CIK cells after chemotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies a type of immune cell therapy called CIK cells for people who have finished chemotherapy for early-to-mid stage esophageal cancer. The treatment aims to use the body's own immune system to fight any remaining cancer cells and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with esophageal cancer (squamous cell carcinoma type).
- Your cancer must be stage I, II, or III – not spread to distant organs.
- You must have completed chemotherapy (any number of cycles).
- You must be well enough to carry out daily activities (ECOG 0 or 1).
- Your blood counts and liver/kidney function must be within normal limits.
- You must not be pregnant, breastfeeding, or have an active serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
This trial studies whether adding an “immunonutrition” nutrition plan to standard chemoradiation can improve outcomes for people with locally advanced, unresectable esophageal squamous cell cancer. It may help the treatment work better by supporting the immune system during therapy.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
This study tests whether a type of immune cell therapy called CIK cells is safe and feasible for people with early-stage liver cancer who have just had their tumor removed. It aims to see if this treatment can help prevent the cancer from coming back.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.